Oncolytic virus for expression of immune checkpoint modulators
AssigneeTransgene S.A.
InventorsNathalie Silvestre, Michel Geist, Karola Rittner, Jean-Baptiste Marchand, Christine Thioudellet
Life of this patent
Estimating the term…
Abstract
The present invention provides an oncolytic virus comprising nucleotide sequence(s) encoding one or more immune checkpoint modulator(s). It also concerns a pharmaceutical composition comprising effective amount of said oncolytic virus and, eventually, a pharmaceutically acceptable vehicle and its use for treating proliferative diseases such as cancers.
Claims24
-25. (canceled)
An oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s), wherein said virus is a vaccinia virus, wherein said one or more immune checkpoint modulator(s) is selected from antibodies that specifically bind to PD-L1, PD-L2, LAG3, Tim3, BTLA, or CTLA4.
A method for treating a proliferative disease, comprising administering an oncolytic virus comprising inserted in its genome a nucleic acid molecule encoding one or more immune checkpoint modulator(s), wherein said virus is a vaccinia virus, wherein said one or more immune checkpoint modulator(s) is selected from antibodies that specifically bind to PD-L1, PD-L2, LAG3, Tim3, BTLA, or CTLA4.
Dependencies are inferred from the claim text.